戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ettes, cigarettes, and other (cigar, hookah, smokeless tobacco).
2 95% CI, 1.03-1.39) compared with never using smokeless tobacco.
3  for pipes, and 1410 participants (2.1%) for smokeless tobacco.
4 ducts: cigarettes, e-cigarettes, cigars, and smokeless tobacco.
5 sues, less is understood about the effect of smokeless tobacco.
6 te smoke may have more profound effects than smokeless tobacco.
7 f quitting which do not include switching to smokeless tobacco.
8 e acute hemodynamic and autonomic effects of smokeless tobacco.
9 r pipe smokers, and 2% were current users of smokeless tobacco.
10 31-2.59], respectively), attempt to purchase smokeless tobacco (adjusted OR, 2.16 [95% CI, 1.90-2.45]
11 ties have implemented a comprehensive ban on smokeless tobacco advertisement, promotion, and sponsors
12  must incorporate further measures to reduce smokeless tobacco and areca nut consumption in populatio
13  consumption, and could be prevented through smokeless tobacco and areca nut control.
14  favoured by most smokers (82%) overall, but smokeless tobacco and bidis were commonly used in India
15                 Furthermore, combined use of smokeless tobacco and cigarettes did not increase overal
16  cancer mortality rate among combined users (smokeless tobacco and cigarettes), based on the rates fo
17  al. describe the association between use of smokeless tobacco and head and neck cancer in 11 US case
18  Few or no associations between each type of smokeless tobacco and HNC were observed among ever cigar
19 tically review policies that are relevant to smokeless tobacco and its context and investigate their
20 , living in a rural area, smoking, consuming smokeless tobacco, and being underweight and the distric
21 use of various tobacco products [cigarettes, smokeless tobacco, and electronic nicotine delivery syst
22 ion on bidis (small hand-rolled cigarettes), smokeless tobacco, and locally brewed alcohols.
23 e exposed organotypic cultures for 3 days to smokeless tobacco aqueous extracts and determined the ch
24   The FDA thus concluded that cigarettes and smokeless tobacco are subject to FDA jurisdiction becaus
25                               Current use of smokeless tobacco at baseline was associated with 1.27-f
26 cigarette/cigar use (302 [3.2%]), and stable smokeless tobacco/cigarette use (141 [1.6%]).
27 0.05) among sole users of cigars, pipes, and smokeless tobacco, compared with their respective refere
28 correlated with number of tins or pouches of smokeless tobacco consumed.
29              Many countries have implemented smokeless tobacco control policies, including those that
30 e extent of the policy implementation gap in smokeless tobacco control, discuss key reasons on why it
31                                          For smokeless tobacco control, many countries have adopted p
32                         We hypothesized that smokeless tobacco could modulate the growth of keratinoc
33 rrent prevalence, 15.7% vs 3.9%; P<.001) and smokeless tobacco (current prevalence, 8.7% vs 0.4%; P<.
34 s, pipe tobacco, hookah, snus pouches, other smokeless tobacco, dissolvable tobacco, bidis, and krete
35 A determined that nicotine in cigarettes and smokeless tobacco does "affect the structure or any func
36  Framework Convention on Tobacco Control for smokeless tobacco (eg, spitting bans).
37             Overall, these data suggest that smokeless tobacco elicits plasma exudation in the oral m
38 lth questionnaire revealed that he was using smokeless tobacco every day.
39  associations were observed between snus and smokeless tobacco excluding snus and incidence of oral h
40 ttes, ENDS, cigars, pipes, hookah, snus, and smokeless tobacco, excluding snus at W1 to W4.
41 effects of cigarette smoke extract (CSE) and smokeless tobacco extract (STE) on cell survival and mot
42                                  Exposure to smokeless tobacco extract was associated with a signific
43                                              Smokeless tobacco extract-induced leaky site formation a
44   Indomethacin had no significant effects on smokeless tobacco extract-induced responses.
45 th Whole Smoke-Conditioned Medium (WS-CM) or Smokeless Tobacco Extracts (STE), and stimulated with li
46 , therefore, were differentially affected by smokeless tobacco extracts in an organotypic tissue mode
47                                 In contrast, smokeless tobacco extracts promoted fibroblast growth at
48 shown that most consumers use cigarettes and smokeless tobacco for pharmacological purposes, includin
49                                   Similarly, smokeless tobacco has the potential to increase the risk
50  including e-cigarettes, cigarettes, cigars, smokeless tobacco, hookah, pipes, and nicotine replaceme
51                                       Use of smokeless tobacco in the United States has been relative
52 eless tobacco, only 138 (77%) Parties define smokeless tobacco in their statutes.
53 d of accelerating the decline in smoking and smokeless tobacco initiation.
54 dical school curricula, specific training in smokeless tobacco intervention, tobacco intervention tra
55                                              Smokeless tobacco is a powerful autonomic and hemodynami
56                                              Smokeless tobacco is associated with pathologic alterati
57                                       Use of smokeless tobacco is becoming a global cause of concern,
58                                              Smokeless tobacco is consumed by 356 million people glob
59   Although awareness of the harms related to smokeless tobacco is growing in many parts of the world,
60  factor for periodontal disease, the role of smokeless tobacco is unclear.
61                         The presence of oral smokeless tobacco lesions among adolescents may be an ea
62                                   Preventing smokeless tobacco lesions and their possible malignant t
63                                              Smokeless tobacco lesions were detected in 1.5% of stude
64 tronger risk factor than chewing tobacco for smokeless tobacco lesions, but the use of either of thes
65 cohol or cigarettes may increase the risk of smokeless tobacco lesions.
66                  These results indicate that smokeless tobacco may also be an important risk factor f
67 s to determine whether an aqueous extract of smokeless tobacco (moist snuff) increases clearance of m
68          57 countries had policies targeting smokeless tobacco, of which 17 had policies outside the
69 approach to control the demand and supply of smokeless tobacco, only 138 (77%) Parties define smokele
70 te the burden of oral cancer attributable to smokeless tobacco or areca nut consumption globally and
71 ancer diagnosed in 2022 were attributable to smokeless tobacco or areca nut consumption, accounting f
72  of oral cancer globally are attributable to smokeless tobacco or areca nut consumption, and could be
73 day database to obtain cases attributable to smokeless tobacco or areca nut consumption.
74              Consuming products that contain smokeless tobacco or areca nut increases the risk of ora
75 reca nut consumption globally and by type of smokeless tobacco or areca nut product in four major con
76 ns (PAFs) using prevalence of current use of smokeless tobacco or areca nut products from national su
77 ctively) mortality compared with never using smokeless tobacco or cigarettes.
78  and key south Asian languages, to summarise smokeless tobacco policies and their impact.
79 eligible studies were included as describing smokeless tobacco policies.
80 ed since the last American Heart Association smokeless tobacco policy statement.
81 itiatives were associated with reductions in smokeless tobacco prevalence of between 4.4% and 30.3% f
82      Outcomes for impact assessment included smokeless tobacco prevalence, uptake, cessation, and hea
83                                 Shammah is a smokeless tobacco product often mixed with lime, ash, bl
84 arction (MI) in people who use snus, a moist smokeless tobacco product, we hypothesized that disconti
85                                              Smokeless tobacco products (STPs) are widely used in cer
86 tobacco users are advised to quit the use of smokeless tobacco products compared to tobacco users.
87                                A plethora of smokeless tobacco products lead to unacceptable exposure
88 han five cigarettes, bidis, a water pipe, or smokeless tobacco products since the quit date), confirm
89 s, six (3%) measure content and emissions of smokeless tobacco products, and 41 (23%) mandate pictori
90   Only 34 (19%) Parties tax or report taxing smokeless tobacco products, six (3%) measure content and
91                                  Its use via smokeless tobacco products, some of which contain saccha
92  with regular and heavy nicotine intake from smokeless tobacco rather than from smoking.
93 n smokeless tobacco users that mentioned any smokeless tobacco relevant policies since 2005, except s
94 cigarette tobacco products (cigar, pipe, and smokeless tobacco) remain unclear, yet such data are req
95 ales bans reported significant reductions in smokeless tobacco sale (6.4%) and use (combined sex 17.6
96                             Current users of smokeless tobacco should be informed of its harm and adv
97 the validity of self-reported information on smokeless tobacco (SLT) use is uncertain.
98 s successfully applied to the analysis of 15 smokeless tobacco (SLT) users and 15 non-users of tobacc
99 on (EU) legislation bans the sale of snus, a smokeless tobacco (SLT) which is considerably less harmf
100 erging alternative tobacco products, such as smokeless tobacco/snus, hookah and water pipes, e-cigare
101              Despite the reported effects of smokeless tobacco (ST) on the periodontium and high prev
102 mucosal lesions frequently occur at sites of smokeless tobacco (ST) placement.
103                                          All smokeless tobaccos stimulated keratinocyte proliferation
104 isease (PAD), but it remains unknown whether smokeless tobacco, such as Swedish snuff (snus), is also
105 A) asserted jurisdiction over cigarettes and smokeless tobacco under the Federal Food, Drug, and Cosm
106 co smoking (1.90 [1.38-2.62]; p<0.0001), and smokeless tobacco use (1.32 [1.03-1.69]; p=0.030) than i
107 ment for confounders, no association between smokeless tobacco use and all-cause (hazard ratio = 1.1,
108 ter understand the cancer risks of exclusive smokeless tobacco use and dual use of smokeless tobacco
109                              Both smoked and smokeless tobacco use and frequency of use vary widely a
110                          Previous studies on smokeless tobacco use and head and neck cancer (HNC) hav
111 rvey was to evaluate the association between smokeless tobacco use and severe active periodontal dise
112 udy was to characterize the relation between smokeless tobacco use and the risk of all-cause and dise
113                                              Smokeless tobacco use appears to be associated with HNC,
114                           Sole and exclusive smokeless tobacco use demonstrated associations with tot
115 e smoking, nicotine replacement therapy, and smokeless tobacco use during pregnancy are associated wi
116 d with significantly higher smoking and male smokeless tobacco use in most Appalachian disparity stat
117             The pooled prevalence of current smokeless tobacco use in pregnant women was lowest in th
118 udy, however, reported an increased trend in smokeless tobacco use in the youth after a total sales b
119                        The health effects of smokeless tobacco use need further documentation.
120                            The difference in smokeless tobacco use prevalence between HIV-positive an
121  Framework Convention on Tobacco Control) on smokeless tobacco use remains unclear.
122           However, global efforts to control smokeless tobacco use trail behind the progress made in
123 orld, few Parties collect or present data on smokeless tobacco use under global or national surveilla
124                                    Exclusive smokeless tobacco use was associated with greater odds o
125  (externalizing problems predicted cigar and smokeless tobacco use).
126 7.8) for tobacco smoking, 3.4% (1.8-5.6) for smokeless tobacco use, and 27.1% (22.8-31.7) for any tob
127 1.9) for tobacco smoking, 2.1% (1.1-3.4) for smokeless tobacco use, and 3.6% (95% CI 2.3-5.2) for any
128 ative prevalence ratios for tobacco smoking, smokeless tobacco use, and any tobacco use separately fo
129 level, country income level, smoking status, smokeless tobacco use, and exposure to dental education
130 luc), in urine and plasma after cessation of smokeless tobacco use, in which NNK is administered p.o.
131 e weak) and reported mainly on prevalence of smokeless tobacco use.
132 Similar associations were noted for pipe and smokeless tobacco use.
133 are associated with meaningful reductions in smokeless tobacco use.
134  its context and investigate their impact on smokeless tobacco use.
135 d at intervals 2-126 days after cessation of smokeless tobacco use.
136                                              Smokeless tobacco, used by more than 300 million people
137 lity of borderline significance among female smokeless tobacco users (hazard ratio = 1.7, 95% CI: 1.0
138 eline (1971-1975) were categorized as either smokeless tobacco users (n = 1,068) or non-smokeless tob
139 r smokeless tobacco users (n = 1,068) or non-smokeless tobacco users (n = 5,737).
140 igarettes), based on the rates for exclusive smokeless tobacco users and exclusive smokers, was highe
141                              The exposure of smokeless tobacco users and smokers to carcinogens and t
142 ays after cessation than at baseline in both smokeless tobacco users and smokers, indicating stereose
143 Gluc (26.1 +/- 15.1 versus 39.6 +/- 26.0) in smokeless tobacco users and smokers.
144            Globally, a smaller proportion of smokeless tobacco users are advised to quit the use of s
145                                Cigarette and smokeless tobacco users had more diverse oral bacterial
146 3.89 +/- 2.43) were significantly shorter in smokeless tobacco users than in smokers.
147 lusion criteria were all types of studies on smokeless tobacco users that mentioned any smokeless tob
148                  The mortality experience of smokeless tobacco users was not significantly greater th
149 ized the oral microbiome of cigarette users, smokeless tobacco users, and non-users over 4 months (fo
150 ants were current cigarette, cigar, pipe, or smokeless tobacco users, respectively.
151 assessed the 20-year mortality experience of smokeless tobacco users.
152                       The user prevalence of smokeless tobacco was 7.7% (7.5% to 8.0%) and prevalence
153                               Current use of smokeless tobacco was associated with coronary heart dis
154  the authors examined whether current use of smokeless tobacco was associated with increased incidenc
155                In conclusion, current use of smokeless tobacco was associated with increased risk of
156                                  Past use of smokeless tobacco was not associated with CVD incidence.
157  adults and never-smokers who currently used smokeless tobacco were twice as likely to have severe ac
158 oncigarette products (eg, cigars, pipes, and smokeless tobacco), which have been understudied because
159 lusive smokeless tobacco use and dual use of smokeless tobacco with other tobacco products, including

 
Page Top